NASDAQ:FLGT
Fulgent Genetics, Inc.
Fulgent Genetics, Inc.'s revenue grew 13.8% in fiscal 2025 to $322.7M while operating margin fell to −28.2%. Free cash flow was −$124.2M, −38.5% of revenue, and the diluted share count rose 1.8%.Summary generated from Fulgent Genetics, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$322.7M
Revenue growth+13.8%
Revenue, 5-yr CAGR−5.2%
Gross margin40.6%
Operating margin−28.2%
Net margin−18.8%
ROICn/a
Return on equity−5.4%
Debt / equityn/a
Free cash flow−$124.2M
FCF margin−38.5%
Share count change+1.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 993 | 619 | 289 | 283 | 323 |
| Operating income | 676 | 179 | −196 | −74 | −91 |
| Net income | 507 | 143 | −168 | −43 | −61 |
| Free cash flow | 515 | 235 | 5 | −19 | −124 |
Recent filings
- 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KOther events
Jun 2, 2026 - 8-KOther events
May 21, 2026 - 8-KDirector or officer change
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 1, 2026